Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.
Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.
She expanded upon the topic on March 1 at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024 during the session, "Barriers to Neural Repair"; her presentation was titled, "Engineering 3D Platforms to Overcome Barriers of Drug Discovery for MS."
Transcript
Can you provide examples of successful applications of engineered 3D platforms in identifying potential therapeutic targets or drug candidates for MS?
There's actually been a few different approaches over the past 5 to 10 years to develop 3D platforms. The key, as I see it, is that you want those 3D platforms to be complex enough to have the features of the brain tissue environment, or the brain lesion environment, in multiple sclerosis but not so complex that you can't actually measure the key outcomes that you would need in drug discovery at scale and rapidly. You have to have a compromise between the engineering reproducibility and the biological complexity.
The way that we and others have been working on that is to use synthetic materials, nonbiological materials, to make these 3D constructs. It's not tissue engineering, we're not trying to grow new brain tissue; we're trying to have a simple enough environment that you approximate the key features that would affect cell and drug response.
Different approaches have included nanoscale electrospun fibers. These look like knots of tiny fibers and glass pillars that look like a pillar of material that cells might be able to engage and wrap around. Both of those approaches are very important in terms of having a 3D environment, but they're also much more stiff than the cells in your actual brain and the brain tissue.
What we've worked on to complement that approach is the 3D printing of polymers that have the stiffness of neurons, as well as the dimensions, the diameter and length span, of neurons. That way, you're not just making something that's engineered and simple, you're making something that has key features that we know affect the cell response and, therefore, the drug response in the brain.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More